The 2nd Ligase Targeting Drug Development Summit returns virtually with new insight and data from pioneers in the field to delve deep into ligase biology, assays to investigate...

FcRn, Fcγ, and IgG studies have been propelled by drug developers recently after Argenx’s potential FDA’s approval of first-in-class FcRn antagonist efgartigimod,...

We are excited for the 6th Advanced R and D Procurement and Sourcing in Pharma Summit returning to Boston in April, reuniting senior leaders to share their stories and lessons...